Table 1. Demographic and clinicopathological data of Ovarian Cancer samples (Training set and independent validation set) and Normal Ovarian samples.

	1st portion of Cases (n = 33)	2nd portion of cases (n = 24)	Training set (Total)	Controls(n = 13)
Age at diagnosis
Median	57	56	57	46
Range	23–79	37–77	23–77	40–55
Follow-up (months)
Median	24	37	30.5
Range	0–228	13–79	0–228
Race
Caucasian	24	24	48	0
African-american	8	0	8	0
Hispanic	0	0	0	13
Unknown	1	0	1	0
Tumor type
EOC*	33	18	51
Germ cell tumor	0	1	1
Metastasis	0	4	4
Unknown	0	1	1
Histology
Serous-papillary	33	11	44
Endometrioid	0	4	4
Mucinous	0	2	2
Undifferentiated	0	1	1
Unknown	0	6	6
Stage
I	15	6	21
II	1	4	5
III	14	12	26
IV	3	1	4
Unknown	0	1	1
Grade
Borderline	12	0	12
G1	0	2	2
G2	8	5	13
G3	13	12	25
GX**	0	1	1
Unknown	0	4	4
Chemotherapy
Yes	11	23	34
No	9	0	9
Unknown	13	1	14
Type of chemotherapy
Platinum/taxol after surgery	0	18	18
Platinum/taxol before and after surgery	0	6	6
Unknown	33	0	33
Recurrence
Yes	4	14	18
No	0	10	10
Unknown	29	0	29
Metastasis
Yes	1	0	1
No	32	0	32
Unknown	0	24	24
Smoking
Smoker	2	5	7
Non-smoker	16	19	35
Unknown	15	0	15
Alcohol
Current	6	2	8
No	12	22	34
Unknown	15	0	15
B. Validation set
Ovarian cancer patients n = 372
Age at diagnosis
Median	61
Range	21–89
Follow-up time (months)
Median	30
Range	0–234
Unknown n = 1
Histology	n	%
Serous	227	61%
Mucinous	43	12%
Endometroid	39	10%
Clear cell	18	5%
Adenocarcinoma	13	3%
Other	31	8%
Unknown	1	0%
Grade
Borderline	5	1%
I	57	15%
II	101	27%
III	154	41%
Undifferentiated	19	5%
Unknown	36	10%
FIGO Stage
I	67	18%
II	30	8%
III	224	60%
IV	51	14%
Residual disease after surgery
<2 cm	184	49%
>2 cm	160	43%
Unknown	28	8%
Chemotherapy
No chemotherapy	56	15%
Platinum-containing	173	47%
Platinum and taxane containing	105	28%
Other	30	8%
Unknown	8	2%
	316
Borderline tumors n = 17
Age at diagnosis
Median	50
Range	19–77
Unknown (n = 5)
Cystadenoma n = 18
Age at diagnosis
Median	30
Range	26–55
Unknown (n = 15)

^*Epithelial ovarian cancer ^** Grade cannot be assessed.